Stockreport

Royalty Pharma PLC (RPRX) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic Acquisitions [Yahoo! Finance]

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF Capital Deployment: Approximately $2.6 billion year-to-date. Share Repurchase: $95 million repurchased in the third quarter, totaling $180 million for the first nine [Read more]